Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cara Therapeutics, Inc.    CARA


Business Summary
Logo Cara Therapeutics, Inc.
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.
Sales per Business
USD (in Million)%USD (in Million)%
License and Milestone Fees19.7599.3%134.4499.5% +580.84%
Clinical Compound0.1400.7%0.6430.5% +359.29%
Sales per region
USD (in Million)%USD (in Million)%
United States19.89100%135.08100% +579.28%
Managers and Directors
Derek T. Chalmers, Dr.562004President, Chief Executive Officer & Director
Thomas Reilly-2020Chief Financial & Accounting Officer
Frèdèrique Menzaghi, Dr.532019Chief Scientific Officer, Senior VP-R&D
Joana Goncalves, Dr.462018Chief Medical Officer
Scott M. Terrillion572016Secretary & Chief Compliance Officer
Martin A. Vogelbaum562015Lead Independent Director
Jeffrey L. Ives, Dr.692014Independent Director
Harrison M. Bains762014Independent Director
Christopher Posner502018Independent Director
Susan Shiff, Dr.-2020Director
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 49,876,763 41,815,942 83.8% 0 0.0% 83.8%
Vifor Pharma AG 7,053,931 14.2%
First Manhattan Co. 3,212,796 6.45%
Rho Ventures 2,799,058 5.62%
Farallon Capital Management LLC 2,465,000 4.95%
T. Rowe Price Associates, Inc. (Investment Management) 2,429,235 4.87%
The Vanguard Group, Inc. 2,130,598 4.28%
Carmignac Gestion SA 1,851,443 3.72%
Carmignac Gestion Luxembourg SA (UK) 1,851,443 3.72%
Chescapmanager LLC 1,314,603 2.64%
BlackRock Fund Advisors 1,253,354 2.52%
Company contact information
CARA Therapeutics, Inc.
4 Stamford Plaza
107 Elm Street
9th floor
Stamford, CT 06902

Phone : +1.203.406.3700
Web : http://www.caratherapeutics.com
Sector Bio Therapeutic Drugs